普鲁卡因胺对血浆胆碱酯酶活性的影响。

The effect of procainamide on plasma cholinesterase activity.

作者信息

Kambam J R, Naukam R J, Sastry B V

机构信息

Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee 37232.

出版信息

Can J Anaesth. 1987 Nov;34(6):579-81. doi: 10.1007/BF03010515.

DOI:10.1007/BF03010515

PMID:3677282

Abstract

The in vitro effect of procainamide on plasma cholinesterase (PCHE) activity in the plasma of ten normal ASA physical status I patients was studied using a kinetic method. The mean plasma cholinesterase activity without procainamide (control) was 0.90 +/- 0.09 units.ml-1. The dibucaine numbers of all the samples were in the normal range of 78 to 86, indicating normal genotypes. The mean plasma cholinesterase activity, in the presence of procainamide in concentrations of 5.0, 10.0, 20.0 and 40.0 micrograms.ml-1, was reduced to 0.73 +/- 0.04, 0.61 +/- 0.03, 0.45 +/- 0.02, and 0.36 +/- 0.01 units.ml-1, respectively. At therapeutic concentrations of 4 to 12 micrograms.ml-1, procainamide inhibited cholinesterase activity 15 to 30 per cent. The authors also showed that the concentration of procainamide required to inhibit 50 per cent of plasma cholinesterase activity was 20 micrograms.ml-1 (I50). The authors conclude that procainamide when tested in vitro had a statistically significant depressant effect on plasma cholinesterase activity at all the concentrations studied.

摘要

采用动力学方法研究了普鲁卡因胺对10例美国麻醉医师协会（ASA）身体状况I级正常患者血浆中血浆胆碱酯酶（PCHE）活性的体外作用。未加普鲁卡因胺时（对照）的平均血浆胆碱酯酶活性为0.90±0.09单位·ml⁻¹。所有样本的地布卡因值在78至86的正常范围内，表明基因型正常。在普鲁卡因胺浓度为5.0、10.0、20.0和40.0微克·ml⁻¹时，平均血浆胆碱酯酶活性分别降至0.73±0.04、0.61±0.03、0.45±0.02和0.36±0.01单位·ml⁻¹。在4至12微克·ml⁻¹的治疗浓度下，普鲁卡因胺抑制胆碱酯酶活性15%至30%。作者还表明，抑制50%血浆胆碱酯酶活性所需的普鲁卡因胺浓度为20微克·ml⁻¹（I50）。作者得出结论，在体外测试时，在所研究的所有浓度下，普鲁卡因胺对血浆胆碱酯酶活性均有统计学上显著的抑制作用。